|
|
Article: NovaBay Pharmaceuticals Expands Management Team; Names Mark Anderson, Ph.D. as Chief Scientific Officer.
- Article from:
- Biotech Week
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
NovaBay Pharmaceuticals, Inc. (NYSE-Amex: NBY), a clinical stage company developing non-antibiotic anti-infective compounds for the treatment or prevention of a wide range of bacterial, viral, and fungal infections, announced that the company has named Mark Anderson, Ph.D. as chief scientific officer, a new position for the company (see also Pharmaceuticals).
"We are adding Mark to our team at a critical time as our partnerships with Alcon and Galderma gather significant clinical momentum and our already robust internal pipeline continues to expand," said Ron Najafi, Ph.D., chairman and chief executive officer of NovaBay. "Mark's expertise in the field of ...
Related newspaper, magazine, and journal articles:
|
|
Article: NovaBay Pharmaceuticals to Present New Pre-Clinical ...
Biotech Week;
September 9, 2009 ;
505 words
...NovaBay Pharmaceuticals, Inc. (NYSE-Amex ... Pharmaceuticals, NovaBay Pharmaceuticals Inc. This article was prepared by Biotech Week editors from staff and ... reports. Copyright 2009, Biotech Week via NewsRx.com.
|
|